FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.
TL;DR
Some differences in treatments used for secondary TNBC may be associated with worse OS, but patients still experienced worse BCSS despite similar treatments, suggesting that more aggressive treatment or consideration for chemotherapy at earlier stage disease is warranted.
OpenAlex 토픽 ·
Fibroblast Growth Factor Research
Proteoglycans and glycosaminoglycans research
Sympathectomy and Hyperhidrosis Treatments
Some differences in treatments used for secondary TNBC may be associated with worse OS, but patients still experienced worse BCSS despite similar treatments, suggesting that more aggressive treatment
APA
Pengfei Zhang, Wuxuan Mei, et al. (2026). FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.. Critical reviews in oncology/hematology, 221, 105205. https://doi.org/10.1016/j.critrevonc.2026.105205
MLA
Pengfei Zhang, et al.. "FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.." Critical reviews in oncology/hematology, vol. 221, 2026, pp. 105205.
PMID
41679523
Abstract
Fibroblast growth factor receptors (FGFRs) are significant oncogenic contributors in lung cancer. The clinical development of FGFR-directed agents represents a promising advancement in precision oncology. However, their efficacy is substantially limited by the emergence of diverse resistance mechanisms. This review summarizes FGFR biology, genomic alterations, and signaling pathways in tumorigenesis. Nonselective tyrosine kinase inhibitors and selective FGFR inhibitors (including pan-FGFR and isoform-specific agents) have shown clinical activity in patients with FGFR-altered lung cancer. Moreover, resistance mechanisms, such as secondary FGFR mutations, bypass signaling, tumor microenvironment (TME) remodeling, and phenotypic switching, are discussed. Innovative approaches, including the second-generation FGFR TKIs, monoclonal antibodies (mAbs), FGF traps, antibody-drug conjugates, and synergistic combinations with immunotherapy or other receptor tyrosine kinase (RTK) inhibitors, are discussed to overcome resistance. Overall, this review offers theoretical insights and proposes strategies to tackle resistance to FGFR-directed treatments in lung cancer.
MeSH Terms
Humans; Lung Neoplasms; Drug Resistance, Neoplasm; Receptors, Fibroblast Growth Factor; Protein Kinase Inhibitors; Signal Transduction; Tumor Microenvironment; Molecular Targeted Therapy; Mutation; Animals; Antineoplastic Agents
같은 제1저자의 인용 많은 논문 (5)
- The FAM gene family and its bridging of male infertility and oncogenic signaling mechanisms: A comprehensive review.
- CIITA was involved in regulating ACSL4-dependent ferroptosis in gastric cancer cells.
- Integrative machine learning identifies a TEAD4-driven endothelial program shaping drug sensitivity and microvascular invasion in HCC.
- Aflatoxin B1 Impairs TACE Efficacy Through Downregulated Carbonic Anhydrase 2: A Bioinformatics Analysis.
- Effect of enriched environment on postoperative sleep and recovery quality in patients undergoing laparoscopic surgery for colorectal cancer.